iPath® B S&P 500® VIX Md-Trm Futs™ ETN SEC Filings

Kineta, LLC (successor by merger to Kineta, Inc.; symbol KA) has filed Post-Effective Amendment No. 1 to four Form S-3 registration statements to deregister every security that remained unsold at the time its merger with TuHURA Biosciences, Inc. closed on 30 June 2025. Because Kineta is now a wholly-owned subsidiary of TuHURA, the previously planned offerings are terminated and the related shelf capacity is no longer required.

• No. 333-252695: resale shelf of 1,460,861 common shares.
• No. 333-269340: resale of 649,346 common shares plus a universal shelf of up to $200 million in mixed securities.
• No. 333-272326: resale of 1,425,179 common shares underlying warrants.
• No. 333-275309: resale of 890,208 common shares underlying warrants.

In total, roughly 4.4 million shares and the $200 million shelf are being removed from registration. The filing is largely administrative: it prevents any further issuance under the old S-3s, eliminates potential SEC reporting obligations tied to those statements, and tidies Kineta’s capital-markets profile under TuHURA’s ownership. Kineta remains a non-accelerated filer and smaller reporting company; no new securities are being offered, and no proceeds will be received.

IMAC Holdings, Inc. (NASDAQ: BACK) filed a restated Form 10-Q/A for the quarter ended 30 June 2024. The amendment corrects previously issued statements after the Audit Committee determined preferred-dividend accounting was materially misstated. The restatement reallocates US$525k of accrued dividends from current liabilities to additional paid-in capital, but does not change total assets or net loss.

Operating results (continuing operations):

• Revenues: US$15.8k (precision-medicine collaboration fees).
• Gross loss: US$(56.3)k as initial lab start-up expenses exceeded sales.
• Operating loss: US$(1.40)m for the quarter; US$(1.81)m YTD.
• Net loss available to common holders: US$(2.03)m for the quarter; US$(2.52)m YTD, or US$(2.16) per share.

Balance sheet (30 Jun 24, restated):

• Cash rose to US$0.89 m from US$0.22 m at 31 Dec 23, helped by US$1.35 m of preferred-stock proceeds and a US$1.0 m net promissory-note raise.
• Total assets: US$2.22 m, including US$1.01 m of newly acquired lab equipment from Theralink.
• Current liabilities: US$3.99 m, driving a working-capital deficit of roughly US$(3.3) m.
• Stockholders’ deficit widened to US$(1.77) m.

Capital & financing actions: 43.5 k shares of Series C-2/D/E/F preferred stock and 2.8 m warrants issued, raising US$1.35 m; US$1.4 m face value 40 % OID notes issued for US$1.0 m cash. Subsequent to the quarter, the company:

• Raised an additional US$0.6 m (US$0.84 m face) via notes.
• Closed a US$3.74 m PIPE for Series G preferred shares and warrants, using US$2.24 m to retire earlier notes.

Strategic shift: All legacy clinics have been sold or closed; ongoing business is now Ignite Proteomics, a precision-medicine lab leveraging Theralink assets for breast-cancer protein analysis and pharma collaborations.

Risk & controls: Management expresses substantial doubt about going-concern status. Two material weaknesses (inadequate accounting resources and segregation-of-duties) remain unresolved. Multiple CMS audits on discontinued operations could trigger material repayments. A Tampa clinic lease is in default.

Outlook: Management must scale Ignite revenues, secure Medicare reimbursement, remediate control gaps and refinance expensive debt to alleviate liquidity pressure and justify the US$51 m preferred-stock liquidation preference outstanding.

On June 30, 2025, MediaAlpha, Inc. (NYSE: MAX) filed a Form 8-K announcing technology-leadership changes and related compensation matters.

Item 5.02 – Executive transition. Chief Technology Officer Eugene Nonko resigned effective June 30, 2025, and simultaneously entered into a Fifth Amendment to his employment agreement to remain as Chief Architect, a non-executive individual-contributor role.

• Base salary: unchanged at $550,000 for 2025.
• Cash incentive bonus: 100 % of salary for 1H25 and 70 % for 2H25, delivering a blended 85 % target, or $467,500, subject to the same corporate metrics used for other senior executives.
• Equity awards: (1) Previously granted RSUs with a $2.75 million grant-date value (50 % of his $5.5 million CTO target opportunity); (2) an additional RSU award valued at $750,000 will be granted 15 July 2025, calculated by dividing $750,000 by the 20-day average share price. All RSUs vest in 16 equal quarterly instalments beginning 15 Aug 2025, contingent upon continued service.

The amendment is filed as Exhibit 10.1.

Item 7.01 – Regulation FD. The company furnished a press release (Exhibit 99.1) announcing the appointment of Amy Yeh as the new Chief Technology Officer. The information under Item 7.01 is considered “furnished,” not “filed,” under the Exchange Act.

Morgan Stanley Finance LLC, guaranteed by Morgan Stanley, is marketing three-year principal-protected market-linked notes tied to the S&P 500 Index (SPX) and the Dow Jones Industrial Average (INDU). The investor’s return is based solely on the worst performing index at the single observation date of July 28 2028.

Key Terms

• Stated principal: $1,000 per note
• Participation rate: 100 % of any index gain
• Maximum payment: 119 %–124 % of principal ($1,190–$1,240)
• Downside protection: payment will not be less than principal, regardless of index loss
• No periodic coupons or interim payments
• Pricing date: July 28 2025; Maturity: August 2 2028
• Estimated value: $951.90 (4.8 % below issue price) reflecting dealer costs and hedging

Risk Highlights

• Limited upside: gains are capped at 19 %–24 %; any index rise above this level is forgone.
• No interest: investors receive no income before maturity.
• Credit exposure: repayment depends on Morgan Stanley’s ability to pay.
• Worst-of structure: a decline in either index nullifies upside from the other.
• Liquidity: the notes are unlisted; secondary trading, if any, could be at a discount.
• Estimated value below par signals embedded fees; price transparency may be limited.

These notes may appeal to investors seeking full principal protection with modest equity upside over a three-year horizon, but they sacrifice dividend income, broader upside participation, and carry issuer credit and liquidity risk.

Barclays Bank PLC is offering unsecured, unsubordinated Global Medium-Term Notes, Series A, that mature on August 3, 2028 and are linked to the price performance of the S&P 500® Index (SPX). The securities are issued in $1,000 denominations and will be sold at par. Investors receive no periodic coupons and the only cash flow occurs at maturity:

• If the SPX Final Value is equal to or above the Initial Value recorded on July 31, 2025, the holder receives principal plus the lesser of (a) the actual index gain and (b) a Maximum Return of 21%. The maximum redemption value is therefore $1,210 per $1,000 note.
• If the SPX Final Value is below the Initial Value, the holder is repaid principal only (no downside participation).

The preliminary estimated value on the pricing date will range between $914.90 and $974.90, meaning the bank’s model value is 2.5% – 8.5% below issue price. Barclays Capital Inc. will receive selling commissions up to 0.80% of principal and may pay concessions to other dealers. The notes will not be listed on an exchange and Barclays is not obliged to provide a secondary market.

Key structural features and risks

• Capped upside / principal protection. Investors trade unlimited equity upside for full principal repayment and a 21% cap.
• Credit exposure to Barclays Bank PLC. All payments depend on the issuer’s solvency; the notes are not FDIC-insured.
• U.K. Bail-in Power. Holders expressly consent to potential write-down, conversion or cancellation of the notes by the U.K. resolution authority.
• Liquidity. No exchange listing and any secondary trading will be solely at the discretion of Barclays Capital Inc.
• Tax. Barclays intends to treat the securities as contingent payment debt instruments; U.S. investors must accrue taxable interest annually even though no cash is received before maturity.

The offering is made under an effective shelf registration (No. 333-287303) via Rule 424(b)(2). Final terms, including Initial Value and total size, will be fixed on or about July 31, 2025.

Barclays Bank PLC is offering Global Medium-Term Notes, Series A, maturing 5 August 2030, that are linked to the price performance of the S&P 500® Index (SPX). The notes are unsecured, unsubordinated obligations of the issuer and are subject to the U.K. bail-in regime.

Key economic terms

• Denomination: minimum US$1,000 and integral multiples thereof
• Initial Valuation Date: 31 Jul 2025  |  Issue Date: 5 Aug 2025
• Final Valuation Date: 31 Jul 2030  |  Maturity Date: 5 Aug 2030
• Payment at maturity:
• If Final Value ≥ Initial Value: US$1,000 + (US$1,000 × min[Reference Asset Return, Maximum Return 43.00%])  → capped maximum payment of US$1,430 per note
• If Final Value < Initial Value: principal returned (US$1,000 per note)
• No periodic coupons and no interim redemption
• Calculation Agent: Barclays Bank PLC
• CUSIP/ISIN: 06746CFN4 / US06746CFN48

Pricing and fees

• Initial Issue Price: 100.00% of principal
• Agent’s commission: up to 0.925% (US$9.25 per US$1,000)
• Issuer’s estimated value on the pricing date: US$889.60–US$969.60, below the issue price, reflecting structuring and hedging costs.

Risk highlights

• Credit risk: repayment depends solely on Barclays Bank PLC; neither FDIC nor FSCS insured.
• Bail-in risk: holders expressly consent to potential write-down/conversion under U.K. Bail-in Power.
• Limited upside: returns capped at 43%; investors do not receive S&P 500 dividends.
• Liquidity risk: notes will not be listed; secondary market making is discretionary.
• Tax complexity: issuer expects to treat the notes as contingent payment debt instruments (CPDIs); investors must accrue taxable interest annually.

Illustrative payoff

• Index rises 10% → payment US$1,100 (10% return)
• Index rises 50% → payment capped at US$1,430 (43% return)
• Index falls any amount → payment US$1,000 (0% return)

The product suits investors seeking principal protection with capped equity upside, willing to accept Barclays credit and bail-in risks, forego interim income, and hold to maturity. It is not appropriate for investors requiring uncapped equity exposure, periodic coupons, or active secondary market liquidity.

Worthington Steel, Inc. (WS) filed a Form 4 reporting that Chief Financial Officer Timothy A. Adams received an award of 9,485 restricted common shares on 06/27/2025 under the company’s 2023 Long-Term Incentive Plan. The grant was made at $0 cost and will vest on 06/27/2028, three years after the grant date. After the transaction, Adams directly holds 45,069 common shares. No sales, derivative security exercises, or Rule 10b5-1 trading plans were disclosed. The filing represents routine executive equity compensation intended to align management and shareholder interests and is not expected to have a material near-term market impact.

Effective June 30, 2025, the Statement of Additional Information (SAI) for John Hancock Financial Opportunities Fund (ticker BTO), John Hancock Investors Trust and John Hancock Premium Dividend Fund is updated to reflect two governance changes:

• Paul Lorentz has resigned as a non-independent Trustee of each fund.
• Kristie M. Feinberg, already serving as each fund’s President and CEO of John Hancock Investment Management, has been appointed as a non-independent Trustee effective the same date and will stand for shareholder election in 2026.

The SAI now lists Ms. Feinberg’s extensive leadership background, including her roles at Manulife Investment Management, Invesco and Oppenheimer Funds, underscoring her experience in finance, strategy and product distribution. The board-class assignment for the Financial Opportunities Fund and Premium Dividend Fund places her term expiring in 2026. The John Hancock Fund Complex comprises 186 funds as of April 30, 2025.

No portfolio, financial or strategic policy changes are disclosed; the supplement is solely a board-composition update, to be read in conjunction with the current SAI.

On June 30, 2025, The Bancorp, Inc. (Nasdaq: TBBK) filed an amended Form 8-K to update investors on the disposition of a non-performing real-estate bridge-lending asset classified as Other Real Estate Owned (OREO). The apartment-complex asset carries a balance of $42.9 million as of June 30, 2025.

The company terminated the sale agreement on June 24, 2025 and demanded that the escrow agent release $3.0 million in earnest-money deposits to the company. Two days later, the buyer objected to the release without citing contractual grounds. Management asserts its entitlement to the funds and "intends to pursue" their release.

Beyond the OREO balance and deposit amount, no incremental financial or earnings data were provided, nor was a new timeline for monetizing the asset disclosed. The remainder of the filing consists of customary forward-looking-statement language and signature blocks.